The Impact of Histological Types on the Efficacy of Angiogenesis Inhibitors in the Treatment of Advanced NSCLC: A Meta-Analysis of Randomized Controlled TrialsOctober 15, 2015
This research assesses the overall efficacy of angiogenesis inhibitor (AI)-containing regimens in the treatment of advanced non-small-cell lung cancer (NSCLC).
Scientists believe that targeting blood vessel cells known as pericytes may offer a potential new therapeutic approach for breast and other cancers.
A novel DNA vaccine is being employed to kill cancer, not by attacking tumor cells, but by targeting the blood vessels that keep them alive.
This fact sheet reviews the use of angiogenesis inhibitors to prevent the formation of new blood vessels, in order to stop or slow the growth or spread of cancerous tumors.
Computerized tomography adds to lactate dehydrogenase (LDH) levels in predicting survival among persons with metastatic melanoma on bevacizumab.
News from the FDA on bosutinib (Bosulif), ziv-aflibercept (Zaltrap), and everolimus oral suspension tablets (Afinitor Disperz).
Thiabendazole, an antifungal drug in clinical use for 40 years, inhibits angiogenesis, slows tumor growth, and reduces vascular density of tumors.
New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.
A newly identified subtype of ovarian cancer that builds its own blood vessels may be vulnerable to agents that block blood vessel formation.
The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
The use of bevacizumab (Avastin) improved progression-free survival in women with ovarian cancer, particularly those at high risk for disease progression.
The FDA has revoked its approval of the breast cancer indication for Avastin (bevacizumab). The anti-angiogenic therapy remains indicated for some colorectal, lung, brain, and kidney cancers.
Using bevacizumab in combination with chemotherapy or biological therapy raises the risk of treatment-related death—but the agent's potential benefits may outweigh the relatively low absolute risk.
A naturally occurring protein inhibits tumor growth and metastasis into secondary organs and has the potential to be developed into an anticancer drug, scientists have found.
Doctors who monitor and help control a patient's blood pressure can minimize the side effects of novel cancer drugs, according to a paper published in the Journal of the National Cancer Institute (2010 May 5;102(9):596-604).
Targeting tumor vasculature by inhibiting angiogenesis is a promising approach for women with advanced ovarian cancer, and clinical trials should designed to ensure that novel agents are evaluated rapidly
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Prognostic Factors for Survival Among Patients With Primary Bone Sarcomas of Small Bones
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- A Call for More Tailored Cancer Education Programs to Improve Screening
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|